ADC Therapeutics Q3 revenue beats estimates on sales volume
ADCT•ADC Therapeutics reported third-quarter revenue of $21.72 million, above the $18.69 million analyst consensus, and a net loss of $25.30 million, narrower than the $33.97 million consensus. The company said its cash runway is expected to extend into 2029 after completing a strategic financial restructuring.
1. Quarterly results
Third-quarter revenue rose year over year to $21.72 million, beating the $18.69 million analyst consensus. The company reported a net loss of $25.30 million, compared with the $33.97 million consensus, and an operating loss of $14.35 million, versus the $21.63 million consensus.
2. Runway and plans
ADC Therapeutics said it completed a strategic financial restructuring that is expected to extend its cash runway into 2029. It plans to use upcoming clinical data to guide development and regulatory strategy, and anticipates potential commercialization of ZYNLONTA in Japan pending regulatory approval.
3. Revenue and expenses
The company attributed the revenue increase primarily to higher product sales volume. It said research and development expenses fell due to discontinued programs and a shift of personnel to commercial activities, while lower selling and marketing expenses reflected reduced marketing and advertising costs.
